DPP-4 Inhibition, Incretins and Islet Function

The study is a single-center study with a cross-over design to examine glycemia, incretin hormones and islet hormones over a 24h study period with standardized breakfast, lunch and dinner after administration of placebo, saxagliptin, vildagliptin or sitagliptin.

Inclusion criteria

• • Caucasian men or women with type 2 diabetes diagnosed according to ICD10 at time of inclusion

• Ongoing treatment with life style adjustment including diet and exercise regimen together with metformin as oral antidiabetic . Metformin therapy should be stable the last three months
• Age 40-75 years
• HbA1c 52-80 mmol/mol (inclusive)
• BMI: 20-40 kg/m2
• Written informed consent has been given
• Capability and willingness to participate in the whole study

Exclusion criteria

• • Liver disease (K70-77 in ICD10) or liver enzymes three times above upper reference range

• Diabetic nephropathy (GFR < 30 mL/min/1.73 m2 or albuminuria) or other causes of renal disease
• Proliferative diabetic retinopathy
• Treatment with any glucose-lowering medication except metformin
• Previous myocardial infarction, coronary heart disease or instable angina pectoris in the last 6 months.
• Symptomatic heart failure (NYHA class II-III)
• Previous surgery on the gastrointestinal tract
• Larger surgical intervention during the last 12 weeks
• Female subject who are pregnant or breast feeding
• Women of child bearing potential not using a highly effective method of birth control
• Treatment with oral steroids, thiazide diuretics, digoxin or growth hormone
• Hypersensitivity to the active substances of to any of the excipients
• Participation in another study the last 4 weeks
• Smoker
• Paracetamol intolerance